Type 2 diabetes and continuous glucose monitoring

Fully subsidizing continuous glucose monitors could overcome disparities in their use by people with diabetes, suggests research conducted in adults enrolled in a US Medicaid program.

Brief, repeated use of real-time continuous glucose monitoring may help to improve glycemic control in people with type 2 diabetes who would otherwise need to escalate to insulin, suggests a small randomized trial.

Skin reactions to glucose monitors and insulin pumps occur in more than a quarter of users but only occasionally result in device discontinuation, research shows.

Early findings from the Hypo-METRICS trial indicate that people with diabetes are unaware on most of the occasions that their blood glucose dips into the hypoglycemic range.

The publication of two SURPASS-3 substudies in The Lancet Diabetes & Endocrinology reveals significant benefits of tirzepatide on liver and abdominal fat in people with type 2 diabetes, as well as on time in target glucose range.

The Dexcom G7 continuous glucose monitor is accurate and well tolerated for up to 10.5 days when worn on the arm or abdomen, a study of adults with diabetes suggests.

Structured monitoring of blood glucose improves its control regardless of the device used, although continuous glucose monitoring is better than self-monitored blood glucose for reducing hypoglycemia, shows a randomized trial.

Discontinuing continuous glucose monitoring leads to the loss of approximately half of the additional time in glycemic range accrued during its use among people with type 2 diabetes, MOBILE study data show.

The results of two studies published in JAMA indicate that real-time continuous glucose monitoring benefits people with type 1 or type 2 diabetes on a range of insulin regimens and from a wide variety of backgrounds.

Predictive low glucose alerts are associated with a reduced frequency and severity of rebound hyperglycemia among people using real-time continuous glucose monitoring, show study findings presented at the virtual ADA 80th Scientific Sessions.

Real-world data presented at the virtual ADA 80th Scientific Sessions highlight the benefits of the FreeStyle Libre continuous glucose monitoring system in reducing acute complications in people with type 1 or type 2 diabetes.

Giving people with type 2 diabetes “wear-and-forget” masked flash glucose monitoring to allow their healthcare providers access to detailed glucose profiles is feasible in primary care, but it is not clear how beneficial this is, show the results of the GP-OSMOTIC trial.

Glycated hemoglobin levels correlate strongly with continuous glucose monitoring-measured average blood glucose and hyperglycemia, but poorly with hypoglycemia, say researchers.

A statement from an ATTD consensus group has streamlined previously agreed continuous glucose monitoring metrics and set out time in range targets.

Flash glucose monitoring confers similar benefits for diabetes patients in the real world as for those using it in clinical trials, research shows.

Continuous glucose monitoring results in modest but significant improvements in glycemic control in patients with type 2 diabetes using basal–bolus insulin, show further results from the DIAMOND trial.

Glycated hemoglobin levels are higher for a given blood glucose level in Black patients with diabetes than they are in White people, shows a continuous glucose monitoring study.

Read the linked commentary from Jay Shubrook.

Accounting for the age of red blood cells strengthens the association between glycated haemoglobin and glucose levels, improving estimates of glycaemic control in patients with diabetes, a study shows.